Dabigatran,
does it really help with Noninferior prevention of six-month recurrent acute venous thromboembolism or related death versus warfarin?
research showsGrade B. Events occurred in 30/1274 (2.4%) versus 27/1265 (2.1%), an absolute difference of 0.4 points (95% CI -0.8 to 1.5). The upper risk-difference and hazard-ratio limits were below the prespecified margins of 3.6 points and 2.75.
ads claimPradaxa is prescribed in Korea, but this result concerns six-month treatment noninferiority, not superiority for every thrombotic condition.
Useful facts when choosing a product
- Dabigatran is a direct thrombin inhibitor.
- Initial parenteral anticoagulation lasted a median nine days.
- Bleeding risk, renal function, and interactions require review.
What the research actually shows
Four gates: ① Defect: noninferiority design. ② Noninferiority design is a listed item. ③ The paper states "randomized, double-blind, noninferiority trial"; margins were "2.75" and "3.6 percentage points." ④ A superiority design could answer this question, so this one avoidable defect gives B1. Replacing effective standard anticoagulation with placebo in acute VTE is ethically impossible, so use of an active control is not counted as a defect.
Why this is classified as B (72)
The hard endpoint (H), clinically meaningful effect (E+), and large hard-outcome trial are three strengths. R1 and B1 each cap the grade at B, producing B, 72. It is not A because there is only one confirmatory trial (R1) and developer funding (I0).
Counterpoint. Noninferiority does not show superiority.
Rejudgment record. Axes and scorer agree — Prespecified RE-COVER noninferiority margins and observed recurrent VTE or related death
| Endpoint | H | Hard endpoint - actual events such as death |
| Replication | R1 | Single confirmatory trial |
| Independence | I0 | Evidence comes only from manufacturer studies |
| Effect size | E+ | Meets the clinically important threshold |
The scoring table and the verdict agree (B).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Six-month noninferiority versus warfarin | B | Both prespecified margins were met. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Study 1 | Multicenter double-blind, double-dummy randomized noninferiority trial | 1265 | Funded, designed, conducted, and analyzed by Boehringer Ingelheim with the steering committee | Symptomatic objectively confirmed recurrent VTE or related death within six months | 30/1274 (2.4%) vs 27/1265 (2.1%); difference 0.4 points (95% CI -0.8 to 1.5); HR upper bound 1.70, within margins 2.75 and 3.6 points | Pivotal large hard-outcome evidence |
Receipt — 1 References
All 1 cited sources were verified for existence at the original page (as of 2026-08-26).
Final verification and publication gate: Codex · Verification cutoff: 2026-08-26 · Corrections: none
Cite this verdict
[Chamgap] Benefit of Dabigatran for Noninferior 6-Month Recurrent Venous Thromboembolism or Related Death — Evidence Grade B·72. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/heart/dabigatran-acute-vte-six-month-recurrence/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.